Latest news with #Aditxt
Business Wire
07-07-2025
- Business
- Business Wire
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced 'bit by bio') Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt's capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026. Aditxt is a social innovation platform that currently operates two programs focused on autoimmunity and early disease and cancer detection. The Company seeks to grow by A cquiring, B uilding, and C apitalizing high-growth ventures across health and biotechnology. The bitXbio Plan marks a deliberate move to broaden the company's capital accessibility and align its current market value with its commercialization roadmap — blending Bitcoin-backed reserve with capital access to support scale and liquidity. 'bitXbio™ is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline,' said Amro Albanna, Co-founder and CEO of Aditxt. 'As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds, and continue to utilize our equity line to support the commercialization of high-impact innovations. We believe that this approach positions us to unlock shareholder value as we strive to execute on planned monetization milestones, starting in 2026.' Plan Highlights Bitcoin-Backed Treasury Strategy Aditxt plans to establish a Bitcoin reserve, subject to the availability of funds, to align its market value in support of its commercialization activities, and to unlock a new class of opportunities with digital asset economies. Equity Line Facility Aditxt intends to strategically deploy capital drawn on its existing equity line facility to meet its existing financial obligations and in support of its commercialization roadmap and upcoming monetization events. Aditxt has approximately $125 million in availability under its common stock purchase agreement with its equity line investor, of which it presently has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025. Planned Capitalization Events in 2026 As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering. The plan reflects Aditxt's broader vision to build a global, socially driven biotech platform, capable of commercializing and monetizing innovation through digital capitalization. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing," "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit bitXbio™ is a trademark of Aditxt, Inc. All rights reserved. Follow Aditxt on:
Business Wire
26-06-2025
- Business
- Business Wire
Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter's NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET. Mr. Albanna will discuss Aditxt's innovation acceleration business model, overview and status of Aditxt's two programs with focus on autoimmunity and early cancer detection, and status of the pending acquisition of Evofem Biosciences, Inc. The livestream will start at 1:00 p.m. ET and will be followed by a question-and-answer session. To learn more about the event, and join, please click: ABOUT: Wall Street Reporter NEXT SUPER STOCK livestream Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next livestream event: About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health, and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close. For more information, please visit Follow Aditxt on:
Business Wire
09-06-2025
- Business
- Business Wire
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ('Evofem'), to Aditxt's Board of Directors. 'We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment of conditions impacting women's lives,' said Amro Albanna, Chairman and CEO of Aditxt. Ms. Pelletier is an expert in women's health, with insight driven by both intensive consumer research and deep commercial experience in the global markets with products addressing women's health spanning every stage in their reproductive journey, from puberty to menopause. Her career in the pharmaceutical industry has spanned more than three decades, during which she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. She is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women's healthcare. During her 10-year tenure as Chief Executive Officer, President and Executive Director of Evofem Biosciences, Ms. Pelletier has led the company through its transition to the public market, the approval of PHEXXI ® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel, the acquisition of SOLOSEC® (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with just one dose, and four consecutive years of net sales growth. Prior to Evofem, Ms. Pelletier was Executive Director at Woman Care Global, an international nonprofit organization focused on creating sustainable supply chains to deliver reproductive healthcare products to women in developing countries. She started her career at G.D. Searle where during her eight year tenure she served in increasingly senior positions and ultimately as Global Franchise Leader. Ms. Pelletier is also a Director of Windtree Therapeutics, Inc. (Nasdaq: WINT), and serves as an Advisory Board Member for several non-profit organizations including CEOs Against Cancer, Girls Inc., and The Center for Community Solutions. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the 'A&R Merger Agreement'), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. For more information, please visit Follow Aditxt on: Aditxt™, Adimune™, ADI-100™, Pearsanta™, and Mitomic™ are trademarks of Aditxt, Inc. PHEXXI ® and SOLOSEC ® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," 'advancing', "aim," 'are working to,' "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated contributions of Ms. Pelletier as a director of Aditxt; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
Yahoo
09-06-2025
- Business
- Yahoo
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
MOUNTAIN VIEW, Calif., June 09, 2025--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment of conditions impacting women's lives," said Amro Albanna, Chairman and CEO of Aditxt. Ms. Pelletier is an expert in women's health, with insight driven by both intensive consumer research and deep commercial experience in the global markets with products addressing women's health spanning every stage in their reproductive journey, from puberty to menopause. Her career in the pharmaceutical industry has spanned more than three decades, during which she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. She is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women's healthcare. During her 10-year tenure as Chief Executive Officer, President and Executive Director of Evofem Biosciences, Ms. Pelletier has led the company through its transition to the public market, the approval of PHEXXI® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel, the acquisition of SOLOSEC® (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with just one dose, and four consecutive years of net sales growth. Prior to Evofem, Ms. Pelletier was Executive Director at Woman Care Global, an international nonprofit organization focused on creating sustainable supply chains to deliver reproductive healthcare products to women in developing countries. She started her career at G.D. Searle where during her eight year tenure she served in increasingly senior positions and ultimately as Global Franchise Leader. Ms. Pelletier is also a Director of Windtree Therapeutics, Inc. (Nasdaq: WINT), and serves as an Advisory Board Member for several non-profit organizations including CEOs Against Cancer, Girls Inc., and The Center for Community Solutions. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. For more information, please visit Follow Aditxt on: LinkedIn: Facebook: Aditxt™, Adimune™, ADI-100™, Pearsanta™, and Mitomic™ are trademarks of Aditxt, Inc. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated contributions of Ms. Pelletier as a director of Aditxt; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. View source version on Contacts Investor and Media Contact IR@ Sign in to access your portfolio
Business Wire
05-06-2025
- Business
- Business Wire
Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt'), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow's Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences' CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women's health, respectively. Friedrich Kapp, M.D, Ph.D. is co-CEO of Adimune, Inc.('Adimune'), which is advancing its lead therapeutic candidate ADI-100™ towards an Investigational New Drug ('IND') submission to enable initiation of clinical trials with the antigen-specific gene therapy. ADI-100 is designed to restore immune tolerance in autoimmune diseases by targeting specific antigens, like glutamic acid decarboxylase, and establish tolerance in organ transplantation. Dr. Kapp, a 30+ year veteran of the pharmaceutical industry, was formerly president of the Therapeutics Business Unit at Schering AG. Chris Mitton was appointed president of Pearsanta, Inc. ('Pearsanta') in September 2024 to drive the advancement of its Mitomic ® diagnostic tests for endometriosis and prostate cancer. A seasoned veteran of the healthcare industry with over 20 years of leadership experience in the medical diagnostics sector and a strong focus on personalized healthcare and molecular oncology diagnostics, Mr. Mitton concurrently serves as CEO of MDNA Life Sciences Inc., a pioneer in the development of liquid biopsy tests. Saundra Pelletier is president, CEO and Chairman of the Board of Evofem Biosciences, Inc. (OTCPK: EVFM) ('EvoFem'). Her deep insight in women's health is driven by intensive consumer research and more than three decades of commercial experience in the global markets with products addressing women's health spanning every stage in their reproductive journey, from puberty to menopause. During her career, including her ten-year tenure at Evofem, she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. Ms. Pelletier is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women's healthcare. Pearsanta and Adimune are wholly-owned subsidiaries of Aditxt. About Aditxt, Inc. Aditxt, Inc. ('Aditxt') is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the planned acquisition of Evofem BioSciences, Inc. ('EvoFem')under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc. (jointly 'the Parties'), as amended (the 'A&R Merger Agreement'), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. For more information, please visit Follow Aditxt on: Aditxt™, Adimune™, ADI-100™, Pearsanta™, are trademarks and Mitomic ® is a registered trademarks of Aditxt, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," 'advancing', "aim," 'are working to,' "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt does not undertake any duty to update any forward-looking statement except as required by law.
